Preview Newsletter
XARELTO Media Monitoring – Week of 4-08-16
-
Xarelto Lawsuit Plaintiff Alleges Blood Thinning Drug Caused Development Of Life-Threatening Internal Bleed
Apr 4, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on details from yet another lawsuit filed against Xarelto manufacturers Janssen Pharmaceuticals (a division of Johnson & Johnson corporation) and Bayer AG. The lawsuit was initially filed in the Eastern District of New York under case number 1:14-cv-04524 before being transferred with thousands of other lawsuits in an MDL consolidation in Eastern Louisiana. The plaintiff involved is a Texas woman who claims that the defendants neglected to properly warn her or other patients regarding potentially dangerous side effects associated with their blood thinner. -
Xarelto Lawsuit Plaintiff Requests $4.35 Million Compensation For Alleged Internal Bleeding Episode
Apr 4, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on the details of a lawsuit which was filed against defendants Bayer AG and Janssen Pharmaceuticals (a division of Johnson & Johnson), as well as several other defendants, in reference to new-generation blood thinner Xarelto. The plaintiff alleges that he is suing because he claims the anticoagulant drug caused him to experience a sudden and uncontrollable bleeding episode. -
Legal-Bay Reports Xarelto News: Lawsuits Now Exceed 3,400 in Number
Apr 4, 2016 | Lawsuitssettlementfunding.com
By Patty Kirby
Legal-Bay LLC, The Lawsuit Settlement Funding Company which operates Lawsuitssettlementfunding.com, reported today that the number of filed lawsuits against Bayer and Johnson & Johnson's subsidiary, Janssen Pharmaceutical Division, has now risen to more than 3,400 in number. -
Xarelto Lawsuit Plaintiffs Allege Anticoagulant Drug Caused Deaths Of Family Members
Apr 5, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on another Xarelto-related lawsuit which has been filed against the blood thinner’s manufacturers Bayer AG and Janssen Pharmaceuticals (a subdivision of Johnson & Johnson corporation). This lawsuit is particularly notable as a group of 10 plaintiffs from several states have united in order to file the complaint because of striking similarities in their allegations. The plaintiffs unanimously claim that the anticoagulant drug Xarelto has caused their family members dangerous and fatal medical complications. -
Chris Bosh Of Miami Heat Faces Another Blood Clot Scare As Xarelto Lawsuit Filings Increase
Apr 5, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on a Business Insider article announcing that Miami Heat basketball star Chris Bosh is struggling with another potential blood clot scare. The article goes on to indicate that Bosh was likely going to spend his days following the injury reviewing options concerning his current basketball season and playing status. The article noted, “no determination will be made about his playing status until he goes through more tests and evaluation,” and that this information was provided by ‘a person with knowledge.’ -
Xarelto Lawsuit Plaintiffs Look To Bellwether Trial Preparations In Eastern Louisiana For MDL No 2592 Complaints
Apr 6, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on bellwether trial preparations which are taking place for more than 2,800 federally-filed Xarelto lawsuits. These lawsuits were consolidated by the U.S. Judicial Panel on Multidistrict Litigation to form MDL No. 2592. This consolidation was possible as the complaints name the same defendants and also share strikingly similar allegations that Xarelto use puts patients at heightened risk for sudden and dangerous bleeding episodes, which can be fatal. These cases continue to rise in number as they prepare for early 2017 bellwether trials, and are centralized in the U.S District Court of Eastern Louisiana and overseen by Judge Eldon Fallon. -
Xarelto Lawsuit Alleges Blood-Thinning Drug Caused Parenchymal Hemorrhage And Subsequent Death
Apr 6, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on another lawsuit referencing Xarelto which has been filed against the drug’s manufacturers Janssen Pharmaceuticals (a division of Johnson & Johnson) and Bayer Healthcare. This complaint is just one of over 2,800 cases which were federally-filed across the nation and later transferred to a single Court and consolidated by the U.S. Judicial Panel on Multidistrict Litigation, forming MDL number 2592. The plaintiffs involved in lawsuits consolidated in the MDL similarly allege that the anticoagulant drug can put users at increased risk for the development of dangerous bleeding episodes, the result of which can be injuries or death. -
Xarelto Lawsuit Numbers Exceed 3,400 In Eastern Louisiana MDL And Philadelphia Mass Tort Program
Apr 6, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on a steady surge of lawsuit filings from plaintiffs with complaints about the blood-thinning drug from across the nation. The complaints are being filed against Xarelto manufacturers Bayer AG and Janssen Pharmaceuticals (a division of Johnson & Johnson). -
Xarelto Lawsuit Plaintiff Alleges Anticoagulant Caused Her Sudden Internal Bleeding Episode
Apr 6, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on the details of a Xarelto-related lawsuit which was filed against Janssen Pharmaceuticals and Bayer AG in the Eastern District of New York. The complaint was filed by a female plaintiff from Texas who claims that the anticoagulant drug’s manufacturers Janssen and Bayer neglected to properly warn consumers about possible dangerous side effects connected to their drug. Her lawsuit was filed under case number 1:14-cv-04524 in a federal court. -
Xarelto Lawsuit Plaintiffs From Nebraska Allege Drug Caused Serious And Permanent Damage
Apr 7, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on yet another lawsuit which was filed against Janssen Pharmaceuticals (a subdivision of Johnson & Johnson corporation) in reference to their new-generation, blood-thinning drug, Xarelto. The plaintiffs filing are a couple from Nebraska who allege that the defendant has manufactured an unsafe anticoagulant drug which will cause the husband to suffer from serious and lasting health complications following a sudden and dangerous bleeding episode. They claim that the health complications have shortened the husband’s life expectancy. -
Xarelto Lawsuit Plaintiffs See Consolidation Of Philadelphia, Pennsylvania Mass Tort Program
Apr 7, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on the continued growth of Xarelto lawsuit numbers which were consolidated to form a mass tort program by the Court of Common Pleas in Philadelphia, Pennsylvania. The involved complaints were unanimously filed against defendants Bayer AG and Johnson & Johnson subsidiary Janssen Pharmaceutical. The plaintiffs filing share strikingly similar claims that the anticoagulant drug Xarelto places patients taking it at heightened risk for the development of sudden, dangerous bleeding episodes which sometimes prove fatal. -
Xarelto Lawsuit Claiming Wrongful Death Filed By South Florida Resident After Husbands Fatal Bleeding Episode
Apr 8, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on the details of another lawsuit filed against Bayer and Janssen Pharmaceuticals (a subdivision of Johnson & Johnson corporation). The plaintiff filing is a widow who alleges that the new-generation, blood-thinning drug Xarelto that they manufacture caused the premature bleeding death of her husband. Her lawsuit was later transferred to the Eastern District of Louisiana to join thousands of others consolidated to form multidistrict litigation No. 2592. -
Xarelto Lawsuit Plaintiff Seeking $4.35 Million For Alleged Internal Bleeding Episode And Lasting Health Damage
Apr 8, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on details from another lawsuit filed against defendants Bayer AG and Janssen Pharmaceuticals (a subdivision of Johnson & Johnson corporation) in addition to several other defendants, discussing new-generation, anticoagulant drug Xarelto. The plaintiff filing claims that he decided to sue after the blood thinner caused him to suffer from a sudden and uncontrollable bleeding episode. -
Xarelto Lawsuit Plaintiff Alleges Manufacturers Use Misleading Advertising Tactics For Blood Thinner
Apr 8, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on a lawsuit which has been filed against Janssen Pharmaceuticals (a subdivision of Johnson & Johnson corporation), and Bayer Healthcare. The plaintiff’s complaint discusses advertising tactics used by the defendants who manufacture the anticoagulant drug Xarelto. In the last 5 years alone, Xarelto has become the subject of more than 3,400 lawsuits from across the United States. Over 2,800 of these have been filed in federal courts and then transferred and consolidated to form multidistrict litigation No. 2592, while more than 620 other Xarelto lawsuits have been formed into a mass tort program by the Court of Common Pleas in Philadelphia, Pennsylvania. -
New York Times Report Draws Questions Surrounding Drug’s FDA Approval For Xarelto Lawsuit Plaintiffs
Apr 8, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on news recently making waves from the New York Times involving two pharmaceutical giants and manufacturers of new-generation, anticoagulant drug Xarelto. The allegations, which have stirred up increased controversy over the drug, state that Bayer AG and Johnson & Johnson division Janssen Pharmaceuticals intentionally mislead the editors of one of the world’s most prestigious medical journals by omitting important data concerning Xarelto. -
Filing of Joint Xarelto Lawsuits Involving Multiple Parties Will Not Be Allowed After May 20
Apr 4, 2016 | AboutLawsuits.com
By Austin Kirk
The U.S. District Judge presiding over all federal Xarelto lawsuits indicates that the filing of joint complaints involving multiple plaintiffs will no longer be permitted after May 20, indicating that each individual who experienced bleeding problems after using the drug must file a separate complaint in the federal multidistrict litigation (MDL). -
Xarelto Litigation Enters New Phase, Prompting Court to Nix Joint Filings
Apr 5, 2016 | Consumer Injury Lawyers
By Sandy Liebhard
The federal litigation involving thousands of Xarelto lawsuits is moving forward rapidly, prompting the Court to terminate the Joint Complaint filing procedures it established last year. According to a March 22nd Pretrial Order issued in the U.S. District Court, Eastern District of Louisiana, joint filings will no longer be permitted as of May 20, 2016. -
Court Confirms 40 Cases for Xarelto Bellwether Discovery Pool
Apr 6, 2016 | The Legal Examiner
By Kendra Goldhirsch
On December 12, 2014, the U.S. Judicial Panel on Multidistrict Litigation consolidated all federally filed Xarelto lawsuits into one court in the Eastern District of Louisiana. Since then, the parties have been involved in choosing potential cases to proceed to early bellwether trials. -
Xarelto Lawsuit MDL Makes Pretrial Progress
Apr 8, 2016 | Top Class Actions
By Paul Tassin
New Xarelto lawsuits continue to be filed as state and federal courts continue pretrial processing of thousands of similar claims.
Client Attorney Privileged/Attorney Work Product/At Request of Counsel
Plaintiff Attorney Press Releases
Plaintiff Attorney Blog Posts
Full Text of Stories Below
-
Apr 4, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on details from yet another lawsuit filed against Xarelto manufacturers Janssen Pharmaceuticals (a division of Johnson & Johnson corporation) and Bayer AG. The lawsuit was initially filed in the Eastern District of New York under case number 1:14-cv-04524 before being transferred with thousands of other lawsuits in an MDL consolidation in Eastern Louisiana. The plaintiff involved is a Texas woman who claims that the defendants neglected to properly warn her or other patients regarding potentially dangerous side effects associated with their blood thinner.
Details of the lawsuit documents show that the woman was prescribed Xarelto by her physician in order to prevent stroke or blood clot risks due to her atrial fibrillation condition. This is a common heart condition which generally makes the heart beat more rapidly than usual. The plaintiff had used Xarelto for just 5 months before suffering from a life-threatening internal bleed, which has now left her with long-term medical needs.
Xarelto was approved by the U.S. Food and Drug Administration in 2011 to treat patients recovering from knee and hip replacement surgeries as well as those suffering from pulmonary embolism, deep vein thrombosis, or atrial fibrillation. The agency gave Xarelto two “black box” warnings, which are the most strict warnings a product can receive before being completely pulled from the market.
Within just five years time, Xarelto lawsuits filed from across the United States now number over 3,400 and have been consolidated into two major groupings. Federally-filed lawsuits were consolidated by the U.S. JPML to form MDL number 2592 in Eastern Louisiana and number over 2,800. In addition, over 620 Xarelto lawsuits have been consolidated to form a mass tort program by the Court of Common Pleas in Philadelphia, Pennsylvania.
As involved plaintiffs look forward to 2017 bellwether trials, Attorney Joseph Osborne is working to help others who have used Xarelto and who believe that the drug has caused them health problems. Affected patients may be entitled to substantial compensation attained through legal action. He wishes to ensure that everyone is given the opportunity to evaluate their legal rights in the matter. To help those interested in further exploring their possibilities, Attorney Osborne is currently offering complimentary Xarelto consultations for qualified individuals.
To request additional Xarelto lawsuit information, or to ask questions, please contact Attorney Joseph Osborne by calling (866) 425-8902.
http://www.digitaljournal.com/pr/2890006
-
Xarelto Lawsuit Plaintiff Requests $4.35 Million Compensation For Alleged Internal Bleeding Episode
Apr 4, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on the details of a lawsuit which was filed against defendants Bayer AG and Janssen Pharmaceuticals (a division of Johnson & Johnson), as well as several other defendants, in reference to new-generation blood thinner Xarelto. The plaintiff alleges that he is suing because he claims the anticoagulant drug caused him to experience a sudden and uncontrollable bleeding episode.
His lawsuit was transferred by the U.S. JPML to be consolidated with thousands of other federally-filed Xarelto lawsuits, forming multidistrict litigation number 2592 in Eastern Louisiana. All involved lawsuits, which now number over 2,800, are being overseen by The Honorable Judge Eldon Fallon, who has tentatively scheduled bellwether trial dates for early 2017.
Among the large number of Xarelto complaints, this one is especially significant as it involves 90-counts and a request by the plaintiff for $4.35 million in compensation. Details from lawsuit paperwork indicate that the plaintiff alleges defendants Bayer and Janssen misleadingly marketed Xarelto as a safe and effective medication for individuals looking to reduce their stroke risk. In addition, he alleges that the defendants neglected to sufficiently warn consumers of possibly dangerous or fatal side effects that he believes can be caused by the drug.
The plaintiff states that Janssen and Bayer may have been very aware that the blood thinner could cause an increased risk of the development of sudden bleeding episodes among patients taking it. He notes that clinical studies conducted on Xarelto help lend support to his argument, and claims that if the defendants had in fact been aware of these potential dangers, they acted with negligence by neglecting to protect the public by informing them of this critical product information. The plaintiff said, “Defendants use the results of the Rocket AF study, the Record studies, and the Einstein studies to promote Xarelto in their promotional materials, including the Xarelto website, which tout the positive results of those studies. However, defendants’ promotional materials fail to similarly highlight the increased risk of gastrointestinal bleeding and bleeding that required transfusion among other serious bleeding concerns.”
Xarelto gained approval by the U.S. Food and Drug Administration (FDA) in 2011. The drug was intended to treat patients with pulmonary embolism, and deep vein thrombosis as well as those recovering from hip and knee replacement surgeries, and this approval was later expanded to include treatment for patients with atrial fibrillation. Today, lawsuits filed in reference to the drug continue to increase in number, and have surpassed 3,400. Federally-filed Xarelto lawsuits have been transferred and consolidated to a single court in Eastern Louisiana by the U.S. Judicial Panel on Multidistrict Litigation, to form MDL number 2592. This MDL is now made up of more than 2,800 complaints filed against Xarelto manufacturers, while another group of over 620 other lawsuits has been consolidated to form a mass tort program by the Court of Common Pleas in Philadelphia, Pennsylvania.
Because filings are predicted to continue to increase in number, Attorney Joseph Osborne is working to assist others who have taken Xarelto and suffered from adverse events that they believe were caused by their use of the blood thinner. He hopes to help ensure that these patients will be given the important opportunity to fully explore their legal rights in the matter. Affected individuals could be entitled to substantial compensation. To assist those interested in further investigating their legal options, Attorney Osborne is currently offering free Xarelto consultations for qualified parties.
To request additional Xarelto lawsuit information, or to ask questions, contact Attorney Osborne by calling (866) 425-8902.
http://www.digitaljournal.com/pr/2889698
-
Legal-Bay Reports Xarelto News: Lawsuits Now Exceed 3,400 in Number
Apr 4, 2016 | Lawsuitssettlementfunding.com
By Patty Kirby
Legal-Bay LLC, The Lawsuit Settlement Funding Company which operates Lawsuitssettlementfunding.com, reported today that the number of filed lawsuits against Bayer and Johnson & Johnson's subsidiary, Janssen Pharmaceutical Division, has now risen to more than 3,400 in number.
The number has almost doubled just within the last few months. Now, according to Digital Journal, more than 2,800 cases have been consolidated in the Eastern District of Louisiana, with an additional 600 lawsuits consolidated by the Court of Common Pleas in Philadelphia, Pennsylvania (MDL 2592).
The lawsuits include claims of serious health problems, long hospital stays, and even death as a result of uncontrollable bleeding events. According to experts, there is no known antidote at this time. For more information or assistance with finding a qualified Xarelto law firm or Xarelto lawyer, contact Legal-Bay directly at: http://lawsuitssettlementfunding.com/contact-us.php
Chris Janish, CEO of Legal-Bay, commented on the recent announcement, "We expected the Xarelto litigation to pick up steam, and with more lawsuits continuing to be filed, it seems that it's happening. We are following this litigation closely, and we want to remind patients who have been injured by the blood thinner that we are committed to helping them."
In order to receive lawsuit funding, you must have retained a Xarelto lawyer first. If you need lawsuit money or pre-settlement funding for your Xarelto claim, Legal-Bay is here to help. Legal-Bay is offering pre-settlement and settlement funding for Xarelto cases as well as other blood thinners – such as Pradaxa – and they are also providing free legal consultations for possible plaintiffs who have not yet retained a Xarelto lawyer. To learn more about Xarelto, Pradaxa, and other blood thinner cases, including services in helping you find a Xarelto lawyer or Xarelto law firm, visit: http://lawsuitssettlementfunding.com/pradaxa-settlement-funding.php
To speak with a live agent to discuss receiving pre-settlement lawsuit money or a free legal consultation on your potential Xarelto or Pradaxa blood thinner lawsuit, call Legal-Bay's toll-free hotline at: 877.571.0405.
You may also apply online at: http://lawsuitssettlementfunding.com and an agent will respond to your request shortly.
http://www.prnewswire.com/news-releases/legal-bay-reports-xarelto-news-lawsuits-now-exceed-3400-in-number-300245254.html
-
Xarelto Lawsuit Plaintiffs Allege Anticoagulant Drug Caused Deaths Of Family Members
Apr 5, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on another Xarelto-related lawsuit which has been filed against the blood thinner’s manufacturers Bayer AG and Janssen Pharmaceuticals (a subdivision of Johnson & Johnson corporation). This lawsuit is particularly notable as a group of 10 plaintiffs from several states have united in order to file the complaint because of striking similarities in their allegations. The plaintiffs unanimously claim that the anticoagulant drug Xarelto has caused their family members dangerous and fatal medical complications.
The plaintiffs make up a group of ten family members in total who are filing as representatives for loved ones who have tragically passed away because of medical complications that occurred while each was taking the blood thinner Xarelto. The lawsuits were filed in a St. Clair County Circuit Court on November 20, 2015, under case number 15-L-670. Further details regarding the complaint show that plaintiffs claim the defendants used fraudulent marketing campaigns for the drug with misleading claims, and missing important product warning information.
Since it’s 2011 approval by the U.S. Food and Drug Administration, Xarelto has also received two “black box” warnings from the agency. These “black box” warnings are the most severe product warnings the FDA is able to attach to a product short of fully removing it from the market. In addition, across the United States, Xarelto lawsuit numbers have surpassed 3,400. Over 2,800 of these lawsuits were consolidated and transferred by the U.S. JPML, forming multidistrict litigation number 2592 in Eastern Louisiana, while over 620 other Xarelto lawsuits have now been formed into a mass tort program in Philadelphia, Pennsylvania by the Court of Common Pleas.
This particular lawsuit names a total of nine defendants, which include the drug’s manufacturers. Plaintiffs claim wrongful death, negligent misrepresentation, strict product liability, and fraud and are requesting, at least, $50,000 in compensation for each of the deceased family members, as well as coverage for legal fees.
As lawsuits concerning Xarelto continue to be filed, Attorney Joseph Osborne is working to help others who used the drug and believe that it caused them to suffer from adverse health events. He wishes to help ensure that all patients who believe they have suffered because of the drug will be provided with the important opportunity to fully investigate their legal options. Affected parties may be entitled to significant compensation. To assist those wishing to look seriously into legal action, Attorney Osborne is currently offering free legal consultations for qualified individuals.
To ask questions about Xarelto lawsuits, or to request further information, please contact Joseph Osborne, Esq. by calling (866) 425-8902.
http://www.digitaljournal.com/pr/2891876
-
Chris Bosh Of Miami Heat Faces Another Blood Clot Scare As Xarelto Lawsuit Filings Increase
Apr 5, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on a Business Insider article announcing that Miami Heat basketball star Chris Bosh is struggling with another potential blood clot scare. The article goes on to indicate that Bosh was likely going to spend his days following the injury reviewing options concerning his current basketball season and playing status. The article noted, “no determination will be made about his playing status until he goes through more tests and evaluation,” and that this information was provided by ‘a person with knowledge.’
Unfortunately, this is not Chris Bosh’s first blood clot scare. The player was the leading scorer for Miami, yet he has battled with regular health struggles. It was reported that Bosh was pulled from the All-Star Game and a 3-point contest because of what was first described as a ‘calf strain’. The article discusses an incident with Bosh from last season, stating the player, “…was shut down at the All-Star break…because a blood clot had found its way to one of his lungs, and that issue is something that Bosh believes started as a calf problem.”
Following the development of his first blood clot, Bosh teamed up with Xarelto manufacturer Janssen Pharmaceuticals (a subdivision of Johnson & Johnson corporation) to be a spokesperson. It was reported that during this time the athlete used the anticoagulant drug for several months. It is noted that it is extremely uncommon and also dangerous for players of various contact sports to be allowed to take blood thinners.
Xarelto is currently the subject of public controversy and more than 3,400 lawsuits which have been filed from across the United States and formed into two major groupings. Federally-filed Xarelto lawsuits have been transferred and consolidated to a single court in Eastern Louisiana by the U.S. Judicial Panel on Multidistrict Litigation. They now form MDL number 2592 which includes more than 2,800 complaints. In addition, over 620 Xarelto lawsuits were consolidated by the Court of Common Pleas in Philadelphia, Pennsylvania, forming a mass tort program there. Plaintiffs involved in all lawsuits share strikingly similar allegations concerning the drug’s link to an increased risk of sudden and dangerous bleeding events among patients using it, some of which have proven to be fatal.
As the involved plaintiffs await early 2017 bellwether trials, Attorney Joseph Osborne is working to help other patients who have taken Xarelto and who believe it has negatively impaired their health. He believes that these individuals are entitled to the important opportunity of evaluating their legal rights in the matter. Affected patients may be entitled to substantial compensation attained through legal action. Those who wish to look into their legal options further are currently offered free legal consultations by Attorney Osborne.
To request more information concerning Xarelto bleeding lawsuits, or to ask questions, please contact Joseph Osborne, Esq. by calling (866) 425-8902.
http://www.wrcbtv.com/story/31641753/chris-bosh-of-miami-heat-faces-another-blood-clot-scare-as-xarelto-lawsuit-filings-increase
-
Apr 6, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on bellwether trial preparations which are taking place for more than 2,800 federally-filed Xarelto lawsuits. These lawsuits were consolidated by the U.S. Judicial Panel on Multidistrict Litigation to form MDL No. 2592. This consolidation was possible as the complaints name the same defendants and also share strikingly similar allegations that Xarelto use puts patients at heightened risk for sudden and dangerous bleeding episodes, which can be fatal. These cases continue to rise in number as they prepare for early 2017 bellwether trials, and are centralized in the U.S District Court of Eastern Louisiana and overseen by Judge Eldon Fallon.
According to a court order given by the Honorable Judge Fallon on December 17, 2015, the process of selecting 40 lawsuits from those consolidated to form the MDL has taken place. The 40 cases selected were to form a bellwether pool, from which ultimately 4 cases will be chosen from to be heard in bellwether trials. These bellwether trials are designed to give those involved in the lawsuits (on both sides) a better idea of how juries might respond to certain pieces of evidence or testimony.
Judge Fallon also indicated that the lawsuits selected by each side were to involve alleged victims from a few different categories: Xarelto users who claim to have suffered from a gastrointestinal bleed, brain hemorrhage, or rectal bleeding while using the drug to prevent strokes, as well as those who took Xarelto and claim to have suffered from gastrointestinal bleeds, brain hemorrhages, or rectal bleeding while they were trying to treat deep vein thrombosis (DVT) or pulmonary embolism conditions.
Today, Xarelto lawsuits number in the thousands and continue to grow as time goes on. They were filed against defendants Bayer AG and Janssen Pharmaceuticals (a division of Johnson & Johnson), who manufacture the drug. Attorney Osborne is working to help other patients who took Xarelto and experienced health problems that they feel were caused by the drug. He wants to help ensure that all affected patients will be given the important opportunity of exploring their legal rights in the matter, as they may be entitled to significant compensation. At this time, Attorney Osborne is offering complimentary legal consultations for qualified parties.
To request additional information on Xarelto bleeding lawsuits, or ask questions, contact Joseph Osborne, Esq. by calling (866) 425-8902.
http://www.digitaljournal.com/pr/2893505
-
Xarelto Lawsuit Alleges Blood-Thinning Drug Caused Parenchymal Hemorrhage And Subsequent Death
Apr 6, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on another lawsuit referencing Xarelto which has been filed against the drug’s manufacturers Janssen Pharmaceuticals (a division of Johnson & Johnson) and Bayer Healthcare. This complaint is just one of over 2,800 cases which were federally-filed across the nation and later transferred to a single Court and consolidated by the U.S. Judicial Panel on Multidistrict Litigation, forming MDL number 2592. The plaintiffs involved in lawsuits consolidated in the MDL similarly allege that the anticoagulant drug can put users at increased risk for the development of dangerous bleeding episodes, the result of which can be injuries or death.
The plaintiff who has filed this particular lawsuit is a daughter filing on behalf of her father who has passed away after using Xarelto. Her complaint was first filed under case number 2:14-cv-00159-cr in a Vermont federal court, but was later transferred to join the others within the MDL. Court documents indicate that the woman’s father died after suffering from a sudden parenchymal hemorrhage (or brain bleed) which the family believes to have been caused by Xarelto. With Xarelto in the man’s system thinning his blood at the time, the physicians attempting to save the father were not able to, and he passed away due to an uncontrollable brain bleed.
Today, Xarelto is the topic of more than 3,400 lawsuits which have been consolidated to form two main groupings: over 2,800 consolidated in the Louisiana MDL as well as more than 620 other Xarelto lawsuits which have been consolidated to form a mass tort program in Philadelphia, Pennsylvania by the Court of Common Pleas. Cases in MDL 2592 grow in number steadily, and have been slowly progressing toward bellwether trial dates set for early 2017.
At this time, attorney Joseph Osborne is working to help other patients who have taken Xarelto and have suffered from adverse health events that they believe were caused by the drug. Affected individuals may be entitled to substantial compensation attained through legal action. Attorney Osborne is working to ensure that all of these patients are provided with the important opportunity to investigate their legal rights in the matter. In addition, to help those interested in evaluating their legal options, Attorney Osborne is currently offering free Xarelto consultations for qualified parties.
To obtain more information, or to ask questions, please contact Joseph Osborne, Esq. at (866) 425-8902.
http://www.cbs19.tv/story/31652269/xarelto-lawsuit-alleges-blood-thinning-drug-caused-parenchymal-hemorrhage-and-subsequent-death
-
Xarelto Lawsuit Numbers Exceed 3,400 In Eastern Louisiana MDL And Philadelphia Mass Tort Program
Apr 6, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on a steady surge of lawsuit filings from plaintiffs with complaints about the blood-thinning drug from across the nation. The complaints are being filed against Xarelto manufacturers Bayer AG and Janssen Pharmaceuticals (a division of Johnson & Johnson).
It was recently reported that lawsuit filings have surpassed 3,400 in number within the United States, and have been consolidated to form two main groupings. Xarelto lawsuits which were federally-filed in courts across the country were transferred and consolidated by the U.S. Judicial Panel on Multidistrict Litigation, forming MDL No. 2592 in Eastern Louisiana. Cases within the MDL are currently being overseen by Judge Eldon Fallon and number more than 2,800. In addition to these Xarelto lawsuits, however, there are over 620 other Xarelto complaints which were consolidated to form a mass tort program by the Court of Common Pleas in Philadelphia, Pennsylvania.
Despite the vast number of plaintiffs involved in these filings, the allegations made against Janssen and Bayer are strikingly similar. The plaintiffs have claimed that use of the drug caused them or their loved ones to experience a range of dangerous bleeding episodes, some of which reportedly proved fatal. Plaintiffs also claim that the defendants acted with negligence by failing to properly warn consumers and medical professionals about potentially dangerous side effects linked to the use of their product.
Plaintiffs anxiously awaiting trial find comfort through the lawsuit results of very similar complaints regarding blood thinner Pradaxa, which were settled just before the cases went to trial. Quite similarly, these complaints increased rapidly in number and quickly included thousands of lawsuits. Pradaxa cases were settled outside of court by the defendant, and many Xarelto lawsuit plaintiffs believe a similar outcome is possible for them.
Many believe that it is likely these lawsuit numbers will continue to grow while early 2017 bellwether trials are awaited. As time passes, Attorney Joseph Osborne is working to help other patients who have taken the anticoagulant drug and who believe that they suffered from health problems because of it. He wants to help ensure that affected patients will be given the opportunity to investigate their legal rights fully. Those affected may be entitled to substantial compensation obtained from legal action. To help answer additional questions for those interested in looking into legal action, Attorney Osborne is offering complimentary legal consultations for qualified individuals at this time.
To request more information on Xarelto lawsuits, or to ask questions, please contact Joseph Osborne, Esq. by calling (866) 425-8902.
http://www.digitaljournal.com/pr/2893186
-
Xarelto Lawsuit Plaintiff Alleges Anticoagulant Caused Her Sudden Internal Bleeding Episode
Apr 6, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on the details of a Xarelto-related lawsuit which was filed against Janssen Pharmaceuticals and Bayer AG in the Eastern District of New York. The complaint was filed by a female plaintiff from Texas who claims that the anticoagulant drug’s manufacturers Janssen and Bayer neglected to properly warn consumers about possible dangerous side effects connected to their drug. Her lawsuit was filed under case number 1:14-cv-04524 in a federal court.
Additional details of this lawsuit show that the plaintiff was prescribed Xarelto by her physician to treat her atrial fibrillation condition, as this heart condition can put patients at increased risk for the occurrence of strokes. The woman claims to have taken Xarelto for just 5 months when she suffered from what she states was a sudden, life-threatening internal bleeding episode. She notes that this bleed has caused long-term damage to her health, and that she will therefore require specialized care well into the future, and incur additional medical bills.
Xarelto has been on the market for five years now, after gaining approval in 2011 from the U.S. Food and Drug Administration (FDA). The agency has since, however, given the drug two “black box” warnings, which are the most strict warnings a product can receive before being pulled from the market for public sale. The drug is the subject of over 3,400 lawsuits today, which have been consolidated to form two main groupings: a group of over 2,800 cases was consolidated by the U.S. JPML to form MDL 2592 in Eastern Louisiana while more than 620 other cases were consolidated by the Court of Common Pleas to form a mass tort program in Philadelphia, Pennsylvania.
Attorney Joseph Osborne understands how these mounting lawsuit allegations may be concerning to those currently taking Xarelto. He is working to assist others who have used the drug and who have also suffered from adverse events and complications that they believe the drug has caused them. Those affected could be entitled to substantial compensation attained through legal action. Attorney Osborne believes that anyone affected should be provided with the critical opportunity to investigate their legal rights fully. To better assist those interested in learning more about legal action, he is also providing free consultations for qualified individuals at this time.
To ask questions concerning Xarelto lawsuits, or to obtain further information on the topic, please contact Attorney Joseph Osborne by calling (866) 425-8902.
http://www.digitaljournal.com/pr/2893902
-
Xarelto Lawsuit Plaintiffs From Nebraska Allege Drug Caused Serious And Permanent Damage
Apr 7, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on yet another lawsuit which was filed against Janssen Pharmaceuticals (a subdivision of Johnson & Johnson corporation) in reference to their new-generation, blood-thinning drug, Xarelto. The plaintiffs filing are a couple from Nebraska who allege that the defendant has manufactured an unsafe anticoagulant drug which will cause the husband to suffer from serious and lasting health complications following a sudden and dangerous bleeding episode. They claim that the health complications have shortened the husband’s life expectancy.
The lawsuit was filed in Eastern Louisiana under case number 2:15-cv-06514, and documents indicate that the husband was prescribed Xarelto in May of 2013. He claims that he took the drug through December of 2013, but stopped using it after he suffered from a dangerous and severe gastrointestinal bleeding episode.
These plaintiffs are not alone in their arguments, unfortunately. Since its 2011 approval by the U.S. Food and Drug Administration, Xarelto has been given two “black box” warnings from the agency. These are the most severe warnings a product can be given before it is fully removed from the market for public sale. In addition, the drug has been the subject of more than 3,400 lawsuits within just 5 years. Plaintiffs filing these lawsuits similarly allege that use of the anticoagulant places those taking it at heightened risk for dangerous bleeding episodes.
Xarelto lawsuits filed in federal courts from across the nation have been transferred and consolidated by the U.S. Judicial Panel on Multidistrict Litigation to form MDL number 2592 in a single Court in Eastern Louisiana. The MDL cases currently number more than 2,800. Additionally, over 600 other Xarelto lawsuits have been consolidated by the Court of Common Pleas in Philadelphia, Pennsylvania to form a mass tort program there.
These Nebraska plaintiffs are requesting compensatory and punitive damages as well as coverage of legal fees. As they await their trial date along with many others, Attorney Joseph Osborne is working to help ensure that others who believe they suffered from health problems after using Xarelto will be given the critical opportunity to explore their legal rights in the matter. Affected patients could be entitled to substantial compensation. To help those wishing to further explore their rights, Attorney Osborne is providing free legal consultations for qualified individuals at this time.
To request additional Xarelto lawsuit information, or to ask questions, please contact Joseph Osborne, Esq. by calling (866) 425-8902.
http://www.keyc.com/story/31672644/xarelto-lawsuit-plaintiffs-from-nebraska-allege-drug-caused-serious-and-permanent-damage
-
Xarelto Lawsuit Plaintiffs See Consolidation Of Philadelphia, Pennsylvania Mass Tort Program
Apr 7, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on the continued growth of Xarelto lawsuit numbers which were consolidated to form a mass tort program by the Court of Common Pleas in Philadelphia, Pennsylvania. The involved complaints were unanimously filed against defendants Bayer AG and Johnson & Johnson subsidiary Janssen Pharmaceutical. The plaintiffs filing share strikingly similar claims that the anticoagulant drug Xarelto places patients taking it at heightened risk for the development of sudden, dangerous bleeding episodes which sometimes prove fatal.
At this time, it has been reported that the mass tort program includes more than 620 cases, and is joined by another 2,800 Xarelto lawsuits which were consolidated in a single court in Eastern Louisiana to form MDL number 2592 by the U.S. Judicial Panel on Multidistrict Litigation. Together, these groupings make up more than 3,400 lawsuits filed against Xarelto manufacturers and expressing similar concerns.
Xarelto was released to the market in 2011 after gaining approval by the U.S. Food and Drug Administration. The FDA, however, has also given Xarelto two “black box” warnings, which are the most severe warnings a product can receive from the agency before being completely pulled from the market. For several years after the product’s initial launch, Xarelto was released without any corresponding antidote, which is another major point of contention among plaintiffs. This meant that if a patient became injured and bled, physicians were unable to easily counteract the effects of the medicine and get the blood to clot. This situation can make even minor bleeds incredibly dangerous.
Traditional blood thinners were instead released to the market with a corresponding antidote in vitamin K. This means that even from the start, if someone using a traditional blood thinner became injured and bled, physicians had the option of treating them with vitamin K which would counteract the blood thinner’s effects and clot their blood.
Today, lawsuits consolidated in both Pennsylvania and Louisiana continue to increase in number as they prepare for early 2017 bellwether trials. As time moves on, Attorney Joseph Osborne is working to help others who have used Xarelto and feel that it caused them health problems. Those affected could be entitled to significant compensation, and deserve the opportunity to fully evaluate their legal rights in the matter. To better ensure that this is possible for everyone deserving, Attorney Osborne is currently offering free legal consultations to qualified parties.
To ask questions regarding Xarelto lawsuits, or to request additional information, please contact Joseph Osborne, Esq. by calling (866) 425-8902.
http://www.digitaljournal.com/pr/2895598
-
Apr 8, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on the details of another lawsuit filed against Bayer and Janssen Pharmaceuticals (a subdivision of Johnson & Johnson corporation). The plaintiff filing is a widow who alleges that the new-generation, blood-thinning drug Xarelto that they manufacture caused the premature bleeding death of her husband. Her lawsuit was later transferred to the Eastern District of Louisiana to join thousands of others consolidated to form multidistrict litigation No. 2592.
The widow’s complaint was initially filed in Southern Florida under case number 9:14-cv-80831. She alleges that Bayer and Janssen acted with negligence by not effectively warning consumers and medical professionals about the potential dangers of their product. She claims that Xarelto caused her husband’s death, as he was using it to prevent a stroke due to his atrial fibrillation condition. While using it, however, he suddenly suffered from a brain bleed known as a subdural hemorrhage. Because he had the blood thinner in his system at the time of the bleed, doctors were unable to stop it or clot his blood. The man died after losing too much blood.
Just five years ago in 2011, the U.S. Food and Drug Administration approved Xarelto and the anticoagulant launched onto the market as a revolutionary new type of blood thinner. It was popular and provided patients with freedoms that traditional blood thinners had been unable to. Today, patients ask–at what cost? Since it’s launch, the drug has been the recipient of two “black box” warnings from the FDA. These are the most strict warnings a product can receive before being fully removed from the market.
For years as well, the product was on the market and used among patients without any corresponding antidote. Traditional blood thinners have an available antidote in vitamin K, so if patients taking them suffer an injury and begin to bleed, physicians have the option of treating them with vitamin K to counteract the blood thinner’s effects and clot their blood. Xarelto patients did not have this option for a number of years. Many plaintiffs who suffered bleeds while the product had no available antidote allege that the manufacturers acted with dangerous negligence by releasing it to market this way.
Xarelto has now become the subject of over 3,400 lawsuits filed by plaintiffs from across the United States. 2,800 of these lawsuits were federally-filed and have been consolidated to form MDL number 2592 in Eastern Louisiana. More than 620 others, however, have been formed into a mass tort program by the Court of Common Pleas in Philadelphia, Pennsylvania.
Attorney Joseph Osborne is currently working to assist other patients who have used Xarelto and feel that the drug caused them to suffer from health complications. Affected patients could be entitled to significant compensation, and deserve the opportunity to explore their legal rights in the matter. To better help those interested in investigating their options, Attorney Joseph Osborne is currently offering free legal consultations for qualified parties.
To request additional Xarelto bleeding lawsuit information, or to ask questions, contact Joseph Osborne, Esq. by calling (866) 425-8902.
http://www.wrcbtv.com/story/31672637/xarelto-lawsuit-claiming-wrongful-death-filed-by-south-florida-resident-after-husbands-fatal-bleeding-episode
-
Apr 8, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on details from another lawsuit filed against defendants Bayer AG and Janssen Pharmaceuticals (a subdivision of Johnson & Johnson corporation) in addition to several other defendants, discussing new-generation, anticoagulant drug Xarelto. The plaintiff filing claims that he decided to sue after the blood thinner caused him to suffer from a sudden and uncontrollable bleeding episode.
The lawsuit was transferred and consolidated by the U.S. Judicial Panel on Multidistrict Litigation to join with thousands of other federally-filed Xarelto lawsuits, forming MDL No. 2592 in Eastern Louisiana. Along with more than 2,400 other plaintiffs, his case will be overseen by Judge Eldon Fallon. In addition, another group of over 620 Xarelto related lawsuits has formed a mass tort program in Philadelphia, Pennsylvania.
Despite this large number of lawsuits, this particular complaint is quite notable. It names additional defendants and involves 90-counts as well as a request for $4.35 million in compensation. The plaintiff claims that the defendants misleadingly marketed Xarelto as a safe and effective drug for patients looking to reduce their risk of strokes. He states that they failed to sufficiently warn consumers of potentially dangerous or fatal side effects that he has linked to the use of the drug.
The plaintiff believes that Janssen and Bayer were likely well aware that the anticoagulant could cause an increased risk for sudden bleeding episodes among patients. He draws attention to clinical studies conducted on the medicine which appear to lend support to this argument, and alleges that if the defendants had in fact been aware of the possibility of these dangers, they acted with extreme negligence by failing to protect consumers by informing them of this critically important product information.
In details of the lawsuit, the plaintiff noted, “Defendants use the results of the Rocket AF study, the Record studies, and the Einstein studies to promote Xarelto in their promotional materials, including the Xarelto website, which tout the positive results of those studies. However, defendants’ promotional materials fail to similarly highlight the increased risk of gastrointestinal bleeding and bleeding that required transfusion among other serious bleeding concerns.”
As Xarelto lawsuit filings are predicted to continue growing in number, Attorney Joseph Osborne is working to help other patients who have used Xarelto and who have suffered from health problems that they believe were caused the drug. He believes that everyone is entitled to explore their legal options in the matter, and notes that those affected may be entitled to significant compensation attained through legal action. To better assist those wanting to learn more, he is currently offering free Xarelto consultations for qualified individuals.
To request more information on Xarelto lawsuits, or to ask questions, please contact Attorney Osborne anytime by calling (866) 425-8902.
http://www.12newsnow.com/story/31676675/xarelto-lawsuit-plaintiff-seeking-435-million-for-alleged-internal-bleeding-episode-and-lasting-health-damage
-
Xarelto Lawsuit Plaintiff Alleges Manufacturers Use Misleading Advertising Tactics For Blood Thinner
Apr 8, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on a lawsuit which has been filed against Janssen Pharmaceuticals (a subdivision of Johnson & Johnson corporation), and Bayer Healthcare. The plaintiff’s complaint discusses advertising tactics used by the defendants who manufacture the anticoagulant drug Xarelto. In the last 5 years alone, Xarelto has become the subject of more than 3,400 lawsuits from across the United States. Over 2,800 of these have been filed in federal courts and then transferred and consolidated to form multidistrict litigation No. 2592, while more than 620 other Xarelto lawsuits have been formed into a mass tort program by the Court of Common Pleas in Philadelphia, Pennsylvania.
The new-generation blood thinner’s advertisements commonly feature celebrity and athlete endorsements and have featured stars like Brian Vickers (NASCAR), Chris Bosh (Miami Heat), Kevin Nealon (SNL), and golf legend Arnold Palmer. In their TV cameos, each star talks about the blood thinner and its benefits, however, according to the plaintiff, they do not properly address some large concerns regarding dangerous risks associated with the product.
Most plaintiffs, unsurprisingly, have a deeply different perspective on Xarelto. They commonly claim that it puts users at increased risk for sudden and dangerous bleeding episodes, some of which, they say, have proven fatal. After gaining FDA approval in 2011, Xarelto has also been given two black box warnings by the agency. These black box warnings are the most strict product warnings a drug can be given before being completely pulled from the market for public sale.
Plaintiffs involved in current Xarelto lawsuits are anxiously awaiting 2017 bellwether trials, and in the meantime, Xarelto lawsuit numbers continue to grow. Those cases which were consolidated by the U.S. Judicial Panel on Multidistrict Litigation to form MDL 2592 are being overseen by the Honorable Judge Eldon Fallon in Eastern Louisiana. Because new lawsuits continue to appear to join those in the current MDL, Attorney Joseph Osborne is working to help others who have used Xarelto and who believe that it has caused them harm. These patients are entitled to explore all of their legal options in the matter, and could also be entitled to significant compensation gained through legal action. To help those wishing to investigate their legal opportunities more, Attorney Osborne is currently offering free Xarelto consultations for those who qualify.
To ask questions concerning Xarelto bleeding lawsuits, or to request more information, please call Joseph Osborne, Esq. at (866) 425-8902.
http://www.digitaljournal.com/pr/2896911
-
New York Times Report Draws Questions Surrounding Drug’s FDA Approval For Xarelto Lawsuit Plaintiffs
Apr 8, 2016 | Bloodthinnerhelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on news recently making waves from the New York Times involving two pharmaceutical giants and manufacturers of new-generation, anticoagulant drug Xarelto. The allegations, which have stirred up increased controversy over the drug, state that Bayer AG and Johnson & Johnson division Janssen Pharmaceuticals intentionally mislead the editors of one of the world’s most prestigious medical journals by omitting important data concerning Xarelto.
Today, over 3,400 lawsuits have been filed regarding Xarelto, all of which involve plaintiffs with alarmingly similar allegations concerning the safety of the blood thinner. The lawsuits have been formed into two groupings at this time: over 2,800 cases have been consolidated by the U.S. Judicial Panel on Multidistrict Litigation, forming MDL number 2592 in Eastern Louisiana, while more than 620 others have been consolidated by the Court of Common Pleas in Philadelphia, Pennsylvania, forming a mass tort program.
This new news creates more for plaintiffs to discuss rather than simply the drug’s alleged dangerous or fatal side effects. A new concern has been generated now that a letter published by The New England Journal of Medicine and authored mostly by researchers at Duke University has been brought to light. Plaintiffs claim that this letter purposefully omitted imperative laboratory data from studies conducted on the drug, which potentially led to a premature approval by the FDA. In addition, plaintiffs state that by being silent about this important issue, the manufacturers and those involved purposefully misled the public. They report that following the mis-publication of this incomplete data, the companies provided the exact same data to regulators in both America and Europe.
The New York Times story discussing this subject appears to insinuate that defendants Bayer and Johnson & Johnson, in addition to some of those who ran Xarelto clinical trials at Duke University, could have lied to the editors of the New England Journal of Medicine and also forced FDA-approval for the drug by omitting critical information for the agency’s consideration.
While plaintiffs involved await answers and 2017 bellwether trials, Attorney Joseph Osborne is working to help others who believe they have been impaired by Xarelto use. He wants to ensure that these patients will be provided with the critical opportunity to fully evaluate their legal rights. Those affected could be entitled to significant compensation gained through legal action. To better assist those wishing to learn more about their legal options, Attorney Osborne is offering complimentary legal consultations for qualified individuals at this time.
To request more Xarelto lawsuit information, or to ask questions, contact Joseph Osborne, Esq. anytime by calling (866) 425-8902.
https://www.pressadvantage.com/story/9172-new-york-times-report-draws-questions-surrounding-drug-s-fda-approval-for-xarelto-lawsuit-plaintiffs
-
Filing of Joint Xarelto Lawsuits Involving Multiple Parties Will Not Be Allowed After May 20
Apr 4, 2016 | AboutLawsuits.com
By Austin Kirk
The U.S. District Judge presiding over all federal Xarelto lawsuits indicates that the filing of joint complaints involving multiple plaintiffs will no longer be permitted after May 20, indicating that each individual who experienced bleeding problems after using the drug must file a separate complaint in the federal multidistrict litigation (MDL).
There are currently more than 4,500 product liability lawsuits pending in the federal court system, which each involve nearly identical allegations that individuals suffered severe or fatal injuries due to side effects of Xarelto, when doctors were unable to control or stop bleeding that developed among users of the novel oral anticoagulant.
Since December 2014, the cases have been centralized before U.S. District Judge Eldon Fallon in the Eastern District of Louisiana for coordinated pretrial proceedings, given the similar questions of fact and law. Procedurally, Judge Fallon previously allowed complaints to be filed in the MDL that contained multiple plaintiffs. However, as the litigation enters a new phase, Judge Fallon indicates that it is now appropriate to terminate the joint complaint filing procedure.
In a pretrial order (PDF) issued March 22, Judge Fallon indicates that after May 20, all efforts to file a complaint in the MDL will be governed by the Federal Rules of Civil Procedure, and joint complaints will no longer be accepted by the Clerk’s office.
The order was issued on the same day as a joint complaint (PDF) was filed on behalf of 10 plaintiffs, which each claim to have suffered Xarelto bleeding injuries. That lawsuit was filed by plaintiffs Sandra Brown, Robert Capps, Bernard Gaus, Jerome Johnson, June Pike, Claude Raye, John Rivers, Arden Runyan, Felton Schley, and Guiseppina Tubbs, which each suffered internal bleeding after ingesting Xarelto.
Xarelto Bleeding Problems
Xarelto (rivaroxoaban) is a new-generation anticoagulant that was introduced in 2011 as a replacement for Coumadin (warfarin), which has been the go-to anticoagulant treatment for decades.
The drug is part of a new class of medications designed to avoid blood clots among individuals at risk for deep vein thrombosis or pulmonary embolism, which have been promoted as easier to use than warfarin. However, since the drugs have hit the market, there have been a large number of reports involving severe and sometimes fatal bleeding problems with Xarelto and other members of this new class, including Pradaxa and Eliquis.
Each of the lawsuits involved in the Xarelto MDL raise nearly identical allegations, indicating that users and the medical community were provided inadequate warnings about the problems with uncontrollable bleeding on Xarelto, and the fact that the anticoagulant lacked a safe and effective reversal agent to allow doctors to quickly stop the blood thinning effects of the drug.
While all blood thinners carry a risk of bleeding injury, the side effects of warfarin can be quickly reversed with a widely known antidote of bleeding occurs. However, there was no Xarelto reversal agent when the drug was introduced. Plaintiffs allege that the drug makers failed to adequately warn doctors about the lack of an antidote.
Similar claims were raised in the litigation over Pradaxa, which was introduced in October 2010, one year before Xarelto hit the market.
More than 4,000 Pradaxa lawsuits were ultimately filed by users of that drug who suffered bleeding injuries. Following several years of litigation, the manufacturer of that medication ultimately agreed to pay $650 million in Pradaxa settlements, with an average of about $150,000 per claim.
As Xarelto bleeding lawyers continue to review potential cases for individuals prescribed the anticoagulant throughout the United States, the number of complaints has surpassed the number of claims involved in the Pradaxa litigation, as the drug has become more widely used in recent years.
Judge Fallon has scheduled a series of early Xarelto bellwether trials in the MDL, which are expected to begin in February 2017 to help the parties gauge how juries may respond to certain evidence and testimony that is likely to be repeated throughout the litigation. While the outcomes of these trials will not be binding on other plaintiffs, they may help the parties negotiate Xarelto settlements that could avoid the need for thousands of individual cases to go before juries nationwide.
http://www.aboutlawsuits.com/xarelto-joint-filings-97513/#sthash.v43f3NvW.dpuf
-
Xarelto Litigation Enters New Phase, Prompting Court to Nix Joint Filings
Apr 5, 2016 | Consumer Injury Lawyers
By Sandy Liebhard
The federal litigation involving thousands of Xarelto lawsuits is moving forward rapidly, prompting the Court to terminate the Joint Complaint filing procedures it established last year. According to a March 22nd Pretrial Order issued in the U.S. District Court, Eastern District of Louisiana, joint filings will no longer be permitted as of May 20, 2016.
More than 4,500 Xarelto bleeding claims have been filed in the Eastern District of Louisiana since the centralized litigation was created in December 2014. According to a recent report from Reuters, the proceeding still ranks among the fastest growing federal multidistrict litigations. All of the pending cases were filed on behalf of patients who allegedly experienced dangerous episodes of uncontrollable bleeding and related complications due to their use of the anticoagulant medication.
Last May, the Court issued an Order that allowed claims involving up to 100 plaintiffs to be filed in a single complaint. The joint filing procedures were intended to minimize the expenses of all parties, and to promote judicial efficiency. According to the Order issued last month, the Xarelto litigation is poised to enter a new phase. Thus, the Court has determined that is now appropriate to terminate the joint filing procedure.
Xarelto Lawsuits Being Prepped for Trial
Xarelto is a new-generation anticoagulant approved by the U.S. Food & Drug Administration (FDA) in 2011. Xarelto lawsuit plaintiffs claim that the drug’s manufacturers wrongly promoted the medication as a superior alternative to warfarin, a blood thinner that has been on the market for decades. Among other things, they point out that internal bleeding associated with warfarin can be stopped via the administration of vitamin K. However, there is currently no approved antidote to reverse Xarelto bleeding.
Court records indicate that the federal Xarelto litigation will convene its first bellwether trials in February 2017. On March 7, 2016, the Court issued an Order identifying 40 Xarelto lawsuits selected for a bellwether discovery pool. These claims will undergo case-specific discovery, and eventually a number will be chosen for trial. Bellwether trials are an important component of most multidistrict litigations, as verdicts in such cases often provide insight into how juries might decide similar lawsuits.
Bernstein Liebhard LLP is representing a number of Xarelto plaintiffs, and our attorneys continue to provide free legal reviews to those who may have been harmed by this medication. To learn more, please call 877-779-1414.
http://www.consumerinjurylawyers.com/xarelto-bleeding-lawsuit-court-terminates-joint-filing-procedures#sthash.wryBy46r.dpuf
-
Court Confirms 40 Cases for Xarelto Bellwether Discovery Pool
Apr 6, 2016 | The Legal Examiner
By Kendra Goldhirsch
On December 12, 2014, the U.S. Judicial Panel on Multidistrict Litigation consolidated all federally filed Xarelto lawsuits into one court in the Eastern District of Louisiana. Since then, the parties have been involved in choosing potential cases to proceed to early bellwether trials.
In a March 7, 2016 order, Judge Eldon E. Fallon, who is overseeing the proceedings, confirmed the 40 Xarelto lawsuits that had been selected to be included in the discovery pool, and which have been scheduled for case-specific depositions over the coming months.
Parties Discussing Discovery Pool in Xarelto Litigation
A discovery pool of cases is created to help the parties gather evidence that may eventually be used in a small, select group of trials. Called “bellwether trials,” these cases help the parties gauge how juries may react to the evidence, which is likely to be repeated over and over again throughout the litigation. Depending on the outcome of those first few cases, the parties may be motivated to go back to the table for settlement negotiations.
In a joint report dated March 11, 2016, the parties indicated that they would be prepared to discuss the 40 cases, which were actually finalized in January. They added that they would also be ready to discuss matters including the plaintiff and defendant fact sheets, preservation orders, interactions with prescribing and treating physicians, and discovery.
All this is in preparation for the first bellwether trials, which are scheduled to begin between February and May 2017.
Xarelto Linked with Hundreds of Adverse Events
The FDA approved Xarelto (rivaroxaban) in July 2011 for the prevention of blood clots in patients going through hip and knee replacement operations. A “newer generation” anticoagulant, Xarelto was advertised as being superior to warfarin, the leading anticoagulant for decades, because it didn’t require dietary changes or blood monitoring.
The drug was later approved for the prevention of stroke in patients with non-valvular atrial fibrillation, and for the treatment and prevention of deep vein thrombosis. Since it was released on the market, however, the drug has been linked with hundreds of reports of adverse events, including blood clots and excessive gastrointestinal bleeding, sometimes leading to death.
Within just a year of its being on the market, Xarelto was named in the Institute of Safe Medicine Practices QuarterWatch publication as having a total of 356 cases of serious, disabling problems linked to, including severe blood clots in younger patients taking the drug after hip and knee replacement surgery.
Manufacturers were later warned by the FDA that their advertisement in the WebMD magazine was “false or misleading because it minimizes the risks associated with Xarelto and makes a misleading claim.” Indeed, many patients who eventually filed Xarelto lawsuits claim that the Janssen Pharmaceuticals and Bayer AG overstated the benefits of the drug, without adequately warning about the risks.
One of the most concerning issues is that there is no readily available antidote to the drug’s effects. Patients presenting with excessive bleeding have to just wait until the drug clears from their system, which can make these events particularly dangerous and potentially even deadly.
http://newyork.legalexaminer.com/defective-dangerous-products/court-confirms-40-cases-for-xarelto-bellwether-discovery-pool/
-
Xarelto Lawsuit MDL Makes Pretrial Progress
Apr 8, 2016 | Top Class Actions
By Paul Tassin
New Xarelto lawsuits continue to be filed as state and federal courts continue pretrial processing of thousands of similar claims.
In the Philadelphia Court of Common Pleas, about 620Xarelto lawsuitsare being processed through a mass tort program under the supervision of Judge Arnold New. Plaintiffs are now allowed to file “efficacy claims” addressing injuries other than bleeding injuries, such as those that result from blood clots.
At the same time, a federal district court in Louisiana is overseeing a multidistrict litigation consisting of over 2,800 Xarelto lawsuits. A recent pretrial order in that litigation set a deadline of May 20, 2016 for filing bundled Xarelto lawsuits covered by a single filing fee. Claims filed after that deadline will need to be filed individually, with a filing fee assessed for each claim.Allegations in Xarelto Lawsuits
Generally, the plaintiffs in these Xarelto lawsuits are former Xarelto patients, and their close relatives, who say they experienced dangerous bleeding injuries and other severe side effects resulting from their use of the blood thinner. They claim that the drug’s manufacturers failed to properly warn about the side effects associated with the drug, particularly the risk of excessive bleeding.
Plaintiffs in the Philadelphia litigation say that in 2012 alone, over 2,000 serious adverse events were reported in association with Xarelto treatment, 151 of which ended in the patient’s death.
Xarelto is a blood thinner originally approved by the FDA in 2011. It’s prescribed to help prevent blood clots and related injuries in patients with atrial fibrillation and those who recently underwent hip or knee replacements.
Despite negative reports, sales of Xarelto have been brisk – which plaintiffs attribute to aggressive marketing by its manufacturers. Sales in the fourth quarter of 2014 reached $414 million, vastly surpassing the rate of sales in previous years.
Xarelto was developed to offer certain advantages over the older blood thinner warfarin. Warfarin had dominated the blood thinner market for over 50 years. However, it requires patients to undergo regular blood testing and dosage adjustments.
Plaintiffs in these Xarelto lawsuits take issue with that lack of blood testing, saying that evidence from clinical trials showed regular blood testing would have made Xarelto treatment safer. They say that blood testing as infrequently as once a year could help identify patients at risk for major bleeding injuries.They argue that manufacturers Bayer and Janssen Pharmaceuticals should have informed doctors and patients about the safety advantages that regular blood testing could provide.
The first trials in these mass tort programs are expected to begin in 2017. More claims are expected to be added between now and then.
Multidistrict litigations, or MDLs, are established where large numbers of lawsuits are filed at roughly the same time, alleging very similar facts — a situation not uncommon in large-scale pharmaceutical products liability litigation. The MDL process allows a single court to handle pretrial issues common to most or all of the claims more efficiently.
The Xarelto MDL is filed under MDL no. 2592 and is being overseen by Judge Eldon Fallon of the U.S. District Court for the Eastern District of Louisiana.
http://topclassactions.com/lawsuit-settlements/lawsuit-news/332207-xarelto-lawsuit-mdl-makes-pretrial-progress/
Client Attorney Privileged/Attorney Work Product/At Request of Counsel
Plaintiff Attorney Press Releases
Plaintiff Attorney Blog Posts
Full Text of Stories Below
Add recipients
Suggested